RT Book, Section
A1 Altkorn, Diane
A2 Stern, Scott D.C.
A2 Cifu, Adam S.
A2 Altkorn, Diane
SR Print(0)
ID 1185264473
T1 Bibliografía
T2 Diagnóstico basado en los síntomas: Una guía basada en evidencias, 4e
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781264268733
LK accessmedicina.mhmedical.com/content.aspx?aid=1185264473
RD 2024/04/16
AB American  Diabetes  Association.  Standard  of  medical  care  in  diabetes—2018.  Diabetes  Care.  2018;41  (Supplement  1):S1–S172.[PubMed:  ]Armstrong  DG,  Coulton  AJM,  Bus  SA.  Diabetic  foot  ulcers  and  their  recurrence.  N  Engl  J  Med.  2017;376:2367–75.[PubMed:  ]Bergenstal  RM,  Gal  RL,  Connor  CG  et  al.  Racial  differences  in  the  relationship  of  glucose  concentrations  and  hemoglobin  A1c  levels.  Ann  Intern  Med.  2017;167:95–102.[PubMed:  ]Butalia  S,  Palda  VA,  Sargeant  RJ  et  al.  Does  this  patient  with  diabetes  have  osteomyelitis  of  the  lower  extremity?  JAMA.  2008;299:806–13.[PubMed:  ]Centers  for  Disease  Control  and  Prevention.  National  Diabetes  Statistic  Report,  2017.  Atlanta,  GA:  Centers  for  Disease  Control  and  Prevention,  U.S.  Dept  of  Health  and  Human  Services;  2017.Chatterjee  S,  Khunti  K,  Davies  MJ.  Type  2  diabetes.  Lancet.  2017;389:2239–51.[PubMed:  ]Fayfman  M,  Pasquel  FJ,  Umpierrez  GE.  Management  of  hyperglycemic  crises.  Med  Clin  North  Am.  2017;101:587–606.[PubMed:  ]Holman  RR,  Paul  SK,  Bethel  A  et  al.  10-year  follow  up  of  intensive  glucose  control  in  type  2  diabetes.  N  Engl  J  Med.  2008;359:1577–89.[PubMed:  ]Inzucchi  SE.  Diagnosis  of  diabetes.  N  Engl  J  Med.  2012;367:542–50.[PubMed:  ]Ismail-Beigi  F,  Moghissi  E,  Tiktin  M  et  al.  Individualizing  glycemic  targets  in  type  2  diabetes  mellitus:  implications  of  recent  clinical  trials.  Ann  Intern  Med.  2011;154:554–9.[PubMed:  ]Kapoor  A,  Page  S,  LaValley  M  et  al.  Magnetic  resonance  imaging  for  diagnosing  foot  osteomyelitis.  Arch  Intern  Med.  2007;167:125–32.[PubMed:  ]Lipska  KJ,  Krumholz  H,  Soones  T,  Lee  SJ.  A  review  of  glycemic  control  in  older  adults  with  type  2  diabetes.  JAMA.  2016;315:1034–45.[PubMed:  ]Lipsky  BA,  Berendt  AR,  Cornia  PB  et  al.  2012  Infectious  Diseases  Society  of  America  clinical  practice  guideline  for  the  diagnosis  and  treatment  of  diabetic  foot  infections.  Clin  Infect  Dis.  2012;54:132–73.The  Action  to  Control  Cardiovascular  Risk  in  Diabetes  Study  Group.  Effects  of  intensive  glucose  lowering  in  type  2  DM.  N  Engl  J  Med.  2008;358:2545–59.[PubMed:  ]The  ADVANCE  Collaborative  Group.  Intensive  blood  glucose  control  and  vascular  outcomes  in  patients  with  type  2  diabetes.  N  Engl  J  Med.  2008;358:2560–72.[PubMed:  ]The  Diabetes  Control  and  Complications  Trial  Research  Group.  The  effect  of  intensive  treatment  of  diabetes  on  the  development  and  progression  of  long-term  complication  in  insulin-dependent  diabetes  mellitus.  N  Engl  J  Med.  1993;329:977–86.[PubMed:  ]UK  Prospective  Diabetes  Study  (UKPDS)  Group.  Intensive  blood-glucose  control  with  sulphonylureas  or  insulin  compared  with  conventional  treatment  and  risk  of  complications  in  patients  with  type  2  diabetes.  (UKPDS  34)  UK  Prospective  Diabetes  Study  Group.  Lancet.  1998;352:837–53.[PubMed:  ]Valencia  WM,  Florez  H.  How  to  prevent  the  microvascular  complications  of  type  2  diabetes  beyond  glucose  control.  BMJ.  2017;356:i6505.[PubMed:  ]Vinik  AI.  Diabetic  sensory  and  motor  neuropathy.  N  Engl  J  Med.  2016;374:1455–64.[PubMed:  ]